Literature DB >> 9765405

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor.

K Grovit-Ferbas1, J Ferbas, V Gudeman, S Sadeghi, M B Goetz, J V Giorgi, I S Chen, W A O'Brien.   

Abstract

The lack of clinical progression in some individuals despite prolonged human immunodeficiency virus type 1 (HIV-1) infection may result from infection with less-pathogenic viral strains. To address this question, we examined the HIV-1 envelope protein from a donor with a low viral burden, stable CD4(+) T-lymphocyte counts, and little evidence of CD8(+) T-cell expansion, activation, or immune activity. To avoid potential changes in envelope function resulting from selection in vitro, envelope clones were constructed by using viral RNA isolated from uncultured peripheral blood mononuclear cells (PBMC). The data showed that recombinant viruses containing envelope sequences derived from RNA isolated from patient PBMC replicated poorly in primary CD4(+) T cells but demonstrated efficient growth in macrophages. The unusual phenotype of these viruses could not be explained solely by differential utilization of coreceptors since the chimeric viruses, as well as an uncloned isolate obtained from the same visit date, can utilize CCR5. In addition, the donor's own cells appeared resistant to infection with chimeric viruses containing autologous envelope sequences. Genotype analysis revealed that the donor was heterozygous for the previously described 32-bp deletion in CCR5 which may be linked with prolonged survival in HIV-1-infected individuals. These data suggest that the changes in envelope sequences confer properties of viral attenuation, which together with the CCR5 +/Delta32 genotype could account for the long-term survival of this patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765405      PMCID: PMC110277     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  93 in total

1.  Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Authors:  M Y Chowers; C A Spina; T J Kwoh; N J Fitch; D D Richman; J C Guatelli
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

2.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity.

Authors:  B D Jamieson; G M Aldrovandi; V Planelles; J B Jowett; L Gao; L M Bloch; I S Chen; J A Zack
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection.

Authors:  C Nielsen; C Pedersen; J D Lundgren; J Gerstoft
Journal:  AIDS       Date:  1993-08       Impact factor: 4.177

6.  Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.

Authors:  J W Balliet; D L Kolson; G Eiger; F M Kim; K A McGann; A Srinivasan; R Collman
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

7.  Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.

Authors:  R I Connor; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.

Authors:  D D Richman; S A Bozzette
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

9.  Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.

Authors:  J Ferbas; A H Kaplan; M A Hausner; L E Hultin; J L Matud; Z Liu; D L Panicali; H Nerng-Ho; R Detels; J V Giorgi
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

10.  The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels.

Authors:  H W Sheppard; W Lang; M S Ascher; E Vittinghoff; W Winkelstein
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177

View more
  7 in total

1.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.

Authors:  K Grovit-Ferbas; J F Hsu; J Ferbas; V Gudeman; I S Chen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

6.  HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Nicole Wyman; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

7.  Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Authors:  Beda Joos; Alexandra Trkola; Marek Fischer; Herbert Kuster; Peter Rusert; Christine Leemann; Jürg Böni; Annette Oxenius; David A Price; Rodney E Phillips; Joseph K Wong; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.